HAEM5:Juvenile xanthogranuloma: Difference between revisions

[unchecked revision][unchecked revision]
m Greg Corboy editing initial page
m Greg Corboy editing initial page
Line 44: Line 44:
==Epidemiology / Prevalence==
==Epidemiology / Prevalence==


Juvenile Xanthogranuloma is a rare histiocytic neoplasm comprising about 0.5% of all pediatric tumors. It is rarely seen in adults. 20-35% cases are congenital and JXG more commonly affects males. Predominantly (>70%) cases arise during the first year of life.
Juvenile Xanthogranuloma is a rare histiocytic neoplasm comprising approximately 0.5% of all pediatric tumors. JXG is seldom seen in in adults. 20-35% cases are congenital, showing male predilection. Predominantly (>70%) cases arise during the first year of life.


==Clinical Features==
==Clinical Features==


JXG lesions are generally asymptomatic; their appearance is typically different in adult and pediatric settings. Infants may present with ≥1 cutaneous, pale yellow-tan, dome-shaped papulonodular lesions. Approximately 5% of patients present with multiple lesions. Typically lesions begin as raised, pink to dark-brown lesions that may become less elevated over time. Spontaneous resolution of some lesions, leaving residual scarring or wrinkling, may occur after months or years. A clinical subtype of JXG called benign cephalic histiocytosis occurs in head and neck of young children, asymptomatic, self-healing papular lesions. The lesions are often large, solitary and persistent in adults; in this context Erdheim–Chester disease is an important differential diagnosis. JXG may occur in patients with neurofibromatosis type 1 and is also reported in the context of Wiskott–Aldrich syndrome.   
JXG lesions are generally asymptomatic; their appearance is typically different in adult and pediatric settings. Infants may present with ≥1 cutaneous, pale yellow-tan, dome-shaped papulonodular lesions. Approximately 5% of patients present with multiple lesions. Typically lesions begin as raised, pink to dark-brown lesions that may become less elevated over time. Spontaneous resolution of some lesions, leaving residual scarring or wrinkling, may occur after months or years. A clinical subtype of JXG called benign cephalic histiocytosis presents with asymptomatic self-healing papular lesions involving the head and neck of young children
 
In adult JXG, lesions are often large, solitary and persistent; in this context Erdheim–Chester disease is an important differential diagnosis.  
 
JXG may occur in patients with neurofibromatosis type 1 and is also reported in Wiskott–Aldrich syndrome.   
{| class="wikitable"
{| class="wikitable"
|'''Signs and Symptoms'''
|'''Signs and Symptoms'''
|Asymptomatic in the beginning
|Initially asymptomatic
≥1 cutaneous papulonodular lesions
≥1 cutaneous papulonodular lesions


Line 57: Line 61:
|-
|-
|'''Laboratory Findings'''
|'''Laboratory Findings'''
|Abnormal blood count, liver enzymes, metabolic tests
|Abnormal liver enzymes and metabolic tests
Cytopenia if bone marrow involved
Cytopenia in cases with bone marrow involvement
|}
|}


==Sites of Involvement==
==Sites of Involvement==


JXG involves and is generally confined to skin, head and neck, upper trunk and proximal extremities. Solitary ocular lesions occur but are rare. Other rare extracutaneous sites of involvement include viscera, and spinal or intracranial regions.   
JXG commonly involves, and is generally confined to, the skin of the head and neck, upper trunk and proximal extremities. Solitary ocular lesions occur but are rare. Other rare extracutaneous sites of involvement include viscera, and paraspinal or intracranial regions.   


==Morphologic Features==
==Morphologic Features==
Line 75: Line 79:
'''Histopathology:'''
'''Histopathology:'''


*Unencapsulated, circumscribed lesions composed of classic histiocytes, large xanthomatous histiocytes, foamy histiocytes and Touton giant cells..
*Unencapsulated, circumscribed lesions composed of classic histiocytes, large xanthomatous histiocytes, foamy histiocytes and Touton giant cells.
*Variable numbers of lymphocytes, eosinophils, plasma cells, neutrophils, and mast cells are often intermixed along with epithelioid cells, spindle cells and oncocytic histiocytes.
*Variable numbers of lymphocytes, eosinophils, plasma cells, neutrophils, and mast cells are often intermixed along with epithelioid cells, spindle cells and oncocytic histiocytes.
*These histiocytes should not  show significant nuclear pleomorphism.
*These histiocytes should not  show significant nuclear pleomorphism.
Line 82: Line 86:


*Mononuclear or multinucleated histiocytes with kidney shaped/oval nuclei, variable numbers of lymphocytes, neutrophils, and eosinophils.
*Mononuclear or multinucleated histiocytes with kidney shaped/oval nuclei, variable numbers of lymphocytes, neutrophils, and eosinophils.
*Touton giant cells or foreign body giant cells may be present
*Touton giant cells or foreign body giant cells may be present.


{| class="wikitable"
{| class="wikitable"
Line 137: Line 141:
|Unknown
|Unknown
|Unknown
|Unknown
|Disseminated JXG with ''GAB2::BRAF'' fusion showed favorable response to treatment with Trametinib (MEK1/2 inhibitor). [5].
|Disseminated JXG with ''GAB2::BRAF'' fusion showed favorable response to treatment with Trametinib (MEK1/2 inhibitor). [5]
|BRAF gene fusions are more often seen in adult and Juvenile JXG as compared with other histiocytic disorders. [10]
|BRAF gene fusions are seen more often in adult and juvenile JXG compared to other histiocytic disorders. [10]
|-
|-
|''RET'' fusions
|''RET'' fusions
Line 147: Line 151:
|Unknown
|Unknown
|Treatment with RET inhibitor Selpercatinib showed dramatic resolution of disfiguring skin lesions. [11]
|Treatment with RET inhibitor Selpercatinib showed dramatic resolution of disfiguring skin lesions. [11]
|Disseminated cutaneous–xanthogranuloma. [11]
|Disseminated cutaneous–xanthogranuloma [11]
|-
|-
|''SYK'' fusions
|''SYK'' fusions
|''CLTC::SYK'' fusions
|''CLTC::SYK'' fusions


-exon 5 or intron 5 of SYK that lead to fusion of ''CLTC'' exon 31 to ''SYK'' exon 6
Exon 5 or intron 5 of SYK that lead to fusion of ''CLTC'' exon 31 to ''SYK'' exon 6


ETV6::SYK fusion
ETV6::SYK fusion
Line 161: Line 165:
|May respond to  oral SYK inhibitors-fostamatinib and entospletinib [12]
|May respond to  oral SYK inhibitors-fostamatinib and entospletinib [12]
|Lacks or shows rare touton giant cells [12]  IHC staining shows strong positivity for p-SYK, positive for cyclin D1 and p-S6. p-Akt negative. [12]
|Lacks or shows rare touton giant cells [12]  IHC staining shows strong positivity for p-SYK, positive for cyclin D1 and p-S6. p-Akt negative. [12]
Children between 2months and 2 years of age with soft tissue involvement and no or limited cutaneous involvement. [12]
Children between 2 months and 2 years of age with soft tissue involvement and no or limited cutaneous involvement. [12]
|-
|-
|''ALK'' fusions/rearrangements
|''ALK'' fusions/rearrangements
Line 181: Line 185:
|Unknown
|Unknown
|Targeted therapy of treatment resistant systemic JXG with Dasatinib showed a steady and dramatic clinical response with a reduction in the size of the primary tumor. [9]
|Targeted therapy of treatment resistant systemic JXG with Dasatinib showed a steady and dramatic clinical response with a reduction in the size of the primary tumor. [9]
|JXG case showing large deletion of CSF1R exons 21 and 22 and  MRC1::PDGFRB fusion was a 3 month old female with large intra-abdominal tumor involving greater omentum, intestinal walls and liver hilum. Achieved complete remission without relapse during 24 years of follow up. [12] IHC staining showed diffuse expression of cyclin D1 in tumor cells.[9] Child with chemotherapy-refractory left chest wall JXG, MRC1::PDGFRB fusion was treated with dasatinib. [12]
|A 3 month old female with a large JXG intra-abdominal tumor involving the greater omentum, intestinal walls and hepatic hilum achieved complete remission without relapse during 24 years of follow up. Testing showed a large deletion of exons 21 and 22 of CSF1R in parallel with MRC1::PDGFRB fusion. [12] IHC staining showed diffuse expression of cyclin D1 in tumor cells.[9] A child with chemotherapy-refractory left chest wall JXG, MRC1::PDGFRB fusion was treated with dasatinib. [12]
|-
|-
|''TBL1XR1::BOD1L1'' fusion (and reciprocal BOD1L1::ABHD10)
|''TBL1XR1::BOD1L1'' fusion (and reciprocal BOD1L1::ABHD10)
|Unknown
|Unknown
|Unknown
|Unknown
Line 190: Line 194:
|Unknown
|Unknown
|Unknown
|Unknown
|Unifocal soft tissue JXG in the nasopharynx. [12]
|Unifocal soft tissue JXG in the nasopharynx [12]
|}
|}
Line 264: Line 268:
|Unknown
|Unknown
|May respond to targeted treatment with (MEK) inhibitors. [5]
|May respond to targeted treatment with (MEK) inhibitors. [5]
|Systemic juvenile xanthogranuloma. [4]
|Systemic juvenile xanthogranuloma [4]
<br />
<br />
|-
|-
|''CSF1R'' mutations
|''CSF1R'' mutations
|Kinase driver mutations
|Kinase driver mutations
Deletions in exon 12
-Deletion in exon 12


Multiple missense mutations in exons 9 and 10
-multiple missense mutations in exons 9 and 10


Large deletions involving exons 21 and 22  
-large deletion of exons 21 and 22  


Alternative CSF1R mutations in exons 9 and 10
-Alternative CSF1R mutations in exons 9 and 10


Missense mutations in exon 10 [12]
-Missense mutations in exon 10
 
[12]
|Unknown
|Unknown
|Unknown
|Unknown
Line 284: Line 290:
|Unknown
|Unknown
|CSF-1R-specific small-molecule inhibitors Pexidartinib and BLZ945 is being studied. [11]
|CSF-1R-specific small-molecule inhibitors Pexidartinib and BLZ945 is being studied. [11]
| Exon 10 mutations affect the extracellular region of CSF-1R and might enhance receptor dimerization. [12]
| -Exon 10 mutations affect the extracellular region of CSF-1R and might enhance receptor dimerization. [12]
 
-Large deletion of CSF1R exons 21 and 22 affects the intracellular c-CBL binding domain leading to defective receptor ubiquitination, and degradation [12]
 
Large deletion of CSF1R exons 21 and 22 affects the intracellular c-CBL binding domain leading to defective receptor ubiquitination, and degradation. [12]




Children less than 2 years of age with soft tissue involvement. [4] [12]
Children less than 2years of age with soft tissue involvement
[4] [12]
|-
|-
|''PIK3CA'' mutations
|''PIK3CA'' mutations
Line 347: Line 352:
|Unknown
|Unknown
|Unknown
|Unknown
|Yes,
|Yes, may indicate pediatric Erdheim–Chester disease.
May indicate pediatric Erdheim–Chester disease.
|Yes
|Yes
Aggressive course
Aggressive course
|Unknown.
|Unknown.
Targeted therapy with BRAF-inhibitor dabrafenib needs to be studied further .
Targeted therapy with BRAF-inhibitor dabrafenib needs to be studied further .
|Pediatric cases with systemic JXG with CNS involvement and ''BRAF'' V600E mutations show male preponderance and are associated with aggressive disease at presentation. In such cases Erdheim–Chester disease is an important differential diagnosis. [6]
|Pediatric cases with systemic JXG with CNS involvement and ''BRAF'' V600E mutations show male preponderance and are associated with aggressive disease at presentation. These cases needs to be  followed up, they probably represent Erdheim–Chester disease.[6]
|}
|}
Note: A more extensive list of mutations can be found in Bioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
Note: A more extensive list of mutations can be found in Bioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
Line 376: Line 380:
==Genetic Diagnostic Testing Methods==
==Genetic Diagnostic Testing Methods==


Other diagnostic tests like next-generation sequencing (NGS), Whole exome sequencing, whole transcriptome sequencing and targeted DNA and/or RNA sequencing that can be helpful for identification of mutations in the ''RAS/RAF/MAPK/ERK'' and ''PI3K/AKT'' pathway genes or ''BRAF, ALK, RET'', and ''NTRK1'' gene rearrangements. These tests are currently not utilized for diagnosis.
Other diagnostic tests like next-generation sequencing (NGS), whole exome sequencing, whole transcriptome sequencing and targeted DNA and/or RNA sequencing that can be helpful for identification of mutations in the ''RAS/RAF/MAPK/ERK'' and ''PI3K/AKT'' pathway genes or ''BRAF, ALK, RET'', and ''NTRK1'' gene rearrangements. These tests are currently not utilized for diagnosis given there are no recognized molecular diagnostic features.


==Familial Forms==
==Familial Forms==


Not listed
JXG may occur in patients with neurofibromatosis type 1 or Wiskott–Aldrich syndrome.


==Additional Information==
==Additional Information==